Abstract
Background
The most important liver diseases that are responsible for the greatest worldwide morbidity and mortality are viral hepatitis (hepatitis B and hepatitis C), alcoholic liver disease (ALD), nonalcoholic fatty liver disease (NAFLD), cirrhosis and hepatocellular carcinoma (CCH) [1] .
It has been estimated that approximately 130-150 million people have chronic hepatitis C (CHC) infection worldwide and about 350.000 to 500.000 people die each year from the disease. The most affected regions are Central and East Asia and North Africa [2] . According to World Health Organization (WHO), in Europe 15 million people have hepatitis C [3] and the disease is responsible for about 86.000 deaths each year [2] . There are evidences showing that viral hepatitis B and C together are the most common causes of liver cirrhosis and hepatocellular carcinoma (57% of cirrhosis cases and 78% of liver carcinoma cases) [3] . In Romania, the prevalence of chronic hepatitis C was estimated at 3.2% [4] , a high prevalence compared to other European countries [5] . It was also noticed that over 99% of patients show genotype 1 [6] .
Prevalence of chronic hepatitis B (CHB) is estimated at 240 million people and more than 780.000 people die every year due to complications of hepatitis B, including cirrhosis and hepatic carcinoma [7] .
NAFLD is the most important cause of liver disease, with a prevalence of 20-40% in Western population [8] . In Europe the prevalence of this disorder varies from 20 to 30% [9] reaching 58-98% in people with overweight and obesity [10] .
It appears that people with chronic hepatic diseases have an increased risk of developing metabolic disorders compared to general population, despite their younger age and lower prevalence of risk factors such as dyslipidemia, obesity and hypertension.
Metabolic dysfunction and chronic hepatitis C
A number of assumptions were proposed to explain the increased prevalence of metabolic disorders in patients with chronic hepatitis C. Insulin resistance (IR) and hyperinsulinemia, hepatic steatosis, chronic inflammation caused by persistent viral replication, proinflammatory cytokines and iron overload, all play an important role in this process that may eventually lead to the occurrence of diabetes mellitus and metabolic syndrome (MetS) [11] .
Hepatitis C may be considered not just a viral disease, but also a metabolic type condition. Results of previous studies have demonstrated the existence of multiple interactions between hepatitis C virus (HCV) and glucose and lipid metabolism.
Glucose metabolism: HCV is acting via multiple metabolic pathways to cause glucose metabolism impairment and IR. Hepatic steatosis: Hepatic steatosis is more frequent (35-81%) in chronic HCV than in the general population (30-35%) [28] . Obesity, diabetes, IR, alcohol, and dyslipidemia are risk factor for steatosis. Fartoux et al. highlighted the fact that the relation between HCV, steatosis and IR is genotype specific, and IR and steatosis are closely related to liver disease progression in patients with HCV [29] . The presence of NAFLD in patients with HCV is associated with metabolic syndrome and is a risk factor for advanced fibrosis [30] .
Current data on the significance of steatosis and the mechanisms of insulin resistance in patients with chronic HCV provides new approaches to this issue. Metabolic disorders and hepatic steatosis in patients with HCV are cofactors involved in the development of complications and also in the poor response to treatment [31] . Correlations of these data led to the idea that the control of metabolic factors is extremely important in the management of HCV.
In the last period many studies have focused on the impact of metabolic disorders and obesity in the natural history of HCV. The effects of diabetes, metabolic syndrome and NAFLD on progression of liver fibrosis are already known [32] . However, the impact of these factors on disease progression in HCV patients is still controversial because of the conflicting results of existing studies [33, 34] .
Lately, there are data that indicate a high prevalence of MetS in HCV patients regardless of the presence of diabetes or obesity. Thus, Oliviera et al. reported a high prevalence of the MetS in patients with chronic hepatitis C, regardless of the presence of diabetes or obesity [35] . 
Chronic hepatitis B and metabolic diseases

Hepatic disease and adipocytokine alterations
Adipocytokines and proinflmmatory cytokines play an important role in metabolic disturbances and liver disease progression.
Patients with HCV show increasing levels of proinflammatory cytokines (TNF-α, interleukin-6, interleukin-1) and decreasing levels of adiponectin, a phenomenon that plays a very important role in the development of insulin resistance. It seems that adiponectin plays a protective role against atherosclerosis and IR. However, results of studies about adiponectin levels in patients with different genotypes of HCV are contradictory. Thus, it has been observed that patients with HCV genotype 3 had lower levels of adiponectin [44] . Another issue related to the increased viral load and genotype 2 was related to the presence of lower adiponectin levels [45] .
In patients with HCV genotype 1 or 3, adiponectin level was associated with steatosis only in men. IR was associated with a decrease in the adiponectin levels in patients with genotype 3 HCV, but not in patients with HCV genotype 1. Adiponectin levels in patients with HCV can be influenced by the presence of metabolic diseases [46] . Furthermore Lago et al. have shown that adiponectin was negatively correlated with IR, steatosis and metabolic syndrome in patients with HCV [47] .
Leptin relationship with HCV was evidenced in multiple studies. In human, leptin levels have been tied to increased production of proinflammatory cytokines (TNF-α, interleukin-6, and interleukin-12) [48] and reduced antiinflammatory cytokines (interleukin-10) [49] . In the human hepatic stellate cells (HSCs), leptin has a pro-fibrogenic effect that promotes intrahepatic inflammation, by stimulating the expression of collagen and the ability of HSCs to express Monocyte Chemoattractant Protein-1 (MCP-1), respectively [50]. The exact mechanism by which leptin promotes fibrosis is still unknown and in vivo studies are inconclusive.
Regarding the implications of resistin, consistent elevated levels were reported in patients with HCV. There are also evidences indicating that it promotes the progression of liver fibrosis, but it was not associated with impaired response to antiviral therapy [51] .
Lecube and collaborators have demonstrated that proinflammatory cytokines in patients with CHC without diabetes and without advanced liver fibrosis present increased levels of TNFR1, TNFR2 and TNF-α and these cytokines were related to HOMA-IR [52] .
There are other adipocytokines (plasminogen activator inhibitor-1 (PAI-1), visfatin, retinol-binding protein 4 (RBP4)) [53] that were associated with increased risk of metabolic disorders in patients with HCV, but further studies are needed to clarify their relationship with metabolic diseases in these patients.
Interactions between hepatitis B infection and adipocytokines remain largely unclear. Hsu et al. showed that serum adiponectin was significantly lower in patients with HBV and also found that HBV patients with HbA1c ≥6.5% had lower levels of adiponectin than those with HbA1c <6.5%. However, further studies are needed to establish the implications of adiponectin in patients with HBV [54] . Another study by Ching-Sheng Hsu et al. showed that patients with chronic HBV infection have significantly higher serum adiponectin and visfatin levels but lower leptin levels than healthy controls. Adipocytokine serum levels correlate independently with HBV viremia, HBsAg levels and stages of liver fibrosis [55] .
Studies that have evaluated the relationship between adipocytokines and the risk of hepatocellular cancer in patients with HBV showed that elevated adiponectin level is independently associated with an increased risk of HCC in these patients. It is possible that adiponectin may play different roles in the pathogenesis of metabolic diseases associated with virus-induced liver disease and the exact mechanisms remain unknown
Cirrhosis and diabetes
Cirrhosis is a late stage of liver fibrosis and has a variety of causes: alcoholism, chronic viral hepatitis (B, C), NASH, etc. The reported incidence of glucose intolerance and diabetes in patients with cirrhosis varies in two studies from 60 to 80%, and from 20 and 60% respectively [56, 57] .
The several mechanisms known to lead to hyperglycemia in cirrhosis include: insulin resistance in liver, skeletal muscle and adipose tissues, decreased hepatic clearance of insulin, porto-systemic shunting of insulin resulting in systemic hyperinsulinemia, hormonal abnormalities (glucagon, growth hormone).
In this population diabetes has particular clinical features: (1) low body mass index or malnutrition, and frequently missing family history of diabetes; (2) it is more frequently associated with hypoglycemic episodes as a result of lack of glycogen stores (3) frequently associated insulin resistance and metabolic imbalance [58, 59] .
Data from patients admitted in 2011 to the National Institute of Diabetes, Nutrition and Metabolic Diseases "Prof. N.C. Paulescu" (6668 patients) were retrospectively analyzed. Liver cirrhosis was present in 2.65% of the patients, the most common causes including chronic hepatitis C, chronic hepatitis B and alcoholic liver disease [60, 61] .
Hepatocellular carcinoma
The last decades have shown an increase in the incidence of HCC in developed countries, in connection with the increased frequency of the HCV infection. Obesity, T2DM, and IR are also well-known risk factors for the development of many types of cancer, including HCC.
In a recent analysis of 13 studies, 11 reports have supported an association between diabetes and development of HCC; individuals with diabetes had 2 times higher risk of developing HCC [62] . The presence of diabetes has remained an independent risk factor for HCC after adjusting for the presence of alcohol consumption or viral hepatitis [63, 64] . IR, hyperinsulinemia and the imbalances between pro-inflammatory and anti-inflammatory cytokines that are associated with the development of NASH, appear to mediate this relation.
The results of a meta-analysis support that diabetes is a negative prognostic factor in patients with HCC, especially those infected with HCV [65] .
Conclusions
Metabolic pathology is commonly seen in patients with liver disease and it requires a complex and multidisciplinary approach. Studies conducted in this field may constitute a good starting point for a series of future research related to the influence of a wide range of metabolic factors, including hyperglycemia, upon the liver fibrosis lesions. Furthermore, the mechanisms that mediate these relations should be clarified in order to develop efficient management strategies. 
